Unveiling the bidirectional role of MMP9: A key player in kidney injury

Guiying Pang1, Ling Ye2, Yinxiao Jiang3

  • 1Anhui University of Traditional Chinese Medicine, Hefei 230000, People's Republic of China; Institute of Innovative Medicine, Biocytogen Pharmaceuticals (Beijing) Co, Ltd., Beijing 102609, People's Republic of China; Joint Graduate School, Yangtze Delta Drug Advanced Research Institute, Nantong 226133, People's Republic of China.

Cellular Signalling
|July 29, 2024
PubMed

Insights

Matrix metalloproteinases (MMPs) play a controversial role in kidney injury. This study explores MMP9

Area of Science:

  • Biochemistry
  • Nephrology
  • Enzymology

Background:

  • Matrix metalloproteinases (MMPs) are zinc-dependent enzymes implicated in various pathologies, including kidney disease.
  • MMP9, a gelatinase B subgroup member, is crucial for extracellular matrix (ECM) remodeling and renal fibrosis.
  • The precise function of MMP9 in kidney disease development remains debated.

Purpose of the Study:

  • To investigate the dual role of MMP9 in kidney injury.
  • To elucidate MMP9's implications in the pathogenesis of renal diseases.
  • To explore the design and mechanism of MMP9 inhibitors.

Main Methods:

  • Literature review of previous studies on MMP9 and kidney injury.
  • Analysis of MMP9's involvement in ECM remodeling and renal fibrosis.
  • Investigation of MMP9 inhibitor design principles.

Main Results:

  • MMP9 exhibits a dual role in kidney injury, contributing to both damage and repair.
  • Its involvement in ECM remodeling is significant in renal fibrosis progression.
  • Previous studies provide a basis for developing targeted MMP9 inhibitors.

Conclusions:

  • MMP9 has a complex, dual role in kidney injury pathogenesis.
  • Understanding MMP9's function is key to developing treatments for renal diseases.
  • This study provides a foundation for designing novel, selective MMP9 inhibitors for kidney disease therapy.